Literature DB >> 22174091

IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation.

Hernan Roca1, Matthew J Craig, Chi Ying, Zachary S Varsos, Paul Czarnieski, Ajjai S Alva, James Hernandez, David Fuller, Stephanie Daignault, Patrick N Healy, Kenneth J Pienta.   

Abstract

Interleukin (IL)-4 plays a critical role in the regulation of immune responses and has been detected at high levels in the tumor microenvironment of cancer patients where it correlates with the grade of malignancy. The direct effect of IL-4 on cancer cells has been associated with increased cell survival; however, its role in cancer cell proliferation and related mechanisms is still unclear. Here it was shown that in a nutrient-depleted environment, IL-4 induces proliferation in prostate cancer PC3 cells. In these cells, under nutrient-depletion stress, IL-4 activates mitogen-activated protein kinases (MAPKs), including Erk, p38, and JNK. Using MAP-signaling-specific inhibitors, it was shown that IL-4-induced proliferation is mediated by JNK activation. In fact, JNK-inhibitor-V (JNKi-V) stunted IL-4-mediated cell proliferation. Furthermore, it was found that IL-4 induces survivin up-regulation in nutrient-depleted cancer cells. Using survivin-short-hairpin-RNAs (shRNAs), it was demonstrated that in this milieu survivin expression above a threshold limit is critical to the mechanism of IL-4-mediated proliferation. In addition, the significance of survivin up-regulation in a stressed environment was assessed in prostate cancer mouse xenografts. It was found that survivin knockdown decreases tumor progression in correlation with cancer cell proliferation. Furthermore, under nutrient depletion stress, IL -4 could induce proliferation in cancer cells from multiple origins: MDA-MB-231 (breast), A253 (head and neck), and SKOV-3 (ovarian). Overall, these findings suggest that in a tumor microenvironment under stress conditions, IL-4 triggers a simultaneous activation of the JNK-pathway and the up-regulation of survivin turning on a cancer proliferation mechanism.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22174091      PMCID: PMC3337359          DOI: 10.1002/jcb.24025

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  50 in total

Review 1.  Signal transduction by the JNK group of MAP kinases.

Authors:  R J Davis
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.

Authors:  Asra Mirza; Marnie McGuirk; Tish N Hockenberry; Qun Wu; Hena Ashar; Stuart Black; Shu Fen Wen; Luquan Wang; Paul Kirschmeier; W Robert Bishop; Loretta L Nielsen; Cecil B Pickett; Suxing Liu
Journal:  Oncogene       Date:  2002-04-18       Impact factor: 9.867

Review 3.  Alternative activation of macrophages.

Authors:  Siamon Gordon
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

4.  Interleukin-4 mediates cell growth inhibition through activation of Stat1.

Authors:  T L Chang; X Peng; X Y Fu
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

Review 5.  AP-1 in mouse development and tumorigenesis.

Authors:  W Jochum; E Passegué; E F Wagner
Journal:  Oncogene       Date:  2001-04-30       Impact factor: 9.867

Review 6.  AP-1 as a regulator of cell life and death.

Authors:  Eitan Shaulian; Michael Karin
Journal:  Nat Cell Biol       Date:  2002-05       Impact factor: 28.824

7.  Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.

Authors:  Mariko Kawakami; Koji Kawakami; Vitaly A Stepensky; Richard A Maki; Howard Robin; Wayne Muller; Syed R Husain; Raj K Puri
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

8.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors.

Authors:  Michael L Whitfield; Gavin Sherlock; Alok J Saldanha; John I Murray; Catherine A Ball; Karen E Alexander; John C Matese; Charles M Perou; Myra M Hurt; Patrick O Brown; David Botstein
Journal:  Mol Biol Cell       Date:  2002-06       Impact factor: 4.138

9.  STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells.

Authors:  Jennifer L Gooch; Barbara Christy; Douglas Yee
Journal:  Neoplasia       Date:  2002 Jul-Aug       Impact factor: 5.715

10.  Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells.

Authors:  J L Gooch; A V Lee; D Yee
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

View more
  32 in total

1.  Interleukin-4 Signaling Plays a Major Role in Urogenital Schistosomiasis-Associated Bladder Pathogenesis.

Authors:  Evaristus C Mbanefo; Chi-Ling Fu; Christina P Ho; Loc Le; Kenji Ishida; Olfat Hammam; Michael H Hsieh
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

2.  Lessons from immunology: IL4R directly promotes mammary tumor metastasis.

Authors:  Katherine T Venmar; Barbara Fingleton
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

3.  The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

Authors:  Mélanie Bruchard; Cédric Rebé; Valentin Derangère; Dieudonnée Togbé; Bernhard Ryffel; Romain Boidot; Etienne Humblin; Arlette Hamman; Fanny Chalmin; Hélène Berger; Angélique Chevriaux; Emeric Limagne; Lionel Apetoh; Frédérique Végran; François Ghiringhelli
Journal:  Nat Immunol       Date:  2015-06-22       Impact factor: 25.606

Review 4.  Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Authors:  Katherine Venmar Bankaitis; Barbara Fingleton
Journal:  Clin Exp Metastasis       Date:  2015-09-18       Impact factor: 5.150

Review 5.  Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13.

Authors:  Miranda A Hallett; Katherine T Venmar; Barbara Fingleton
Journal:  Cancer Res       Date:  2012-12-07       Impact factor: 12.701

6.  αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor.

Authors:  Huimin Lu; Tao Wang; Jing Li; Carmine Fedele; Qin Liu; Jianzhong Zhang; Zhong Jiang; Dhanpat Jain; Renato V Iozzo; Shelia M Violette; Paul H Weinreb; Roger J Davis; Daniel Gioeli; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino
Journal:  Cancer Res       Date:  2016-07-22       Impact factor: 12.701

7.  Reversal of tumor immune inhibition using a chimeric cytokine receptor.

Authors:  Ann M Leen; Sujita Sukumaran; Norihiro Watanabe; Somala Mohammed; Jacqueline Keirnan; Ryu Yanagisawa; Usanarat Anurathapan; David Rendon; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Juan F Vera
Journal:  Mol Ther       Date:  2014-03-20       Impact factor: 11.454

8.  IL4 receptor ILR4α regulates metastatic colonization by mammary tumors through multiple signaling pathways.

Authors:  Katherine T Venmar; Kathy J Carter; Daniel G Hwang; E Ashley Dozier; Barbara Fingleton
Journal:  Cancer Res       Date:  2014-06-19       Impact factor: 12.701

Review 9.  Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system.

Authors:  Xiaohui Wang; Zhiqiang Wu; Wei Qiu; Ping Chen; Xiang Xu; Weidong Han
Journal:  Front Med       Date:  2020-08-13       Impact factor: 4.592

10.  IL-4 Counteracts the Cytotoxic Effects of Peripheral Blood Mononuclear Cells on Hormone-sensitive Prostate Cancer Cells.

Authors:  Holger H H Erb; Zoran Culig; Matthias B Stope
Journal:  In Vivo       Date:  2021 Jul-Aug       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.